Bicara Therapeutics Inc. Common Stock (BCAX) — Financial statements
Income statement, balance sheet, and cash flow for Bicara Therapeutics Inc. Common Stock — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue & Gross Profit | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | |||||
| R&D Expenses | 125↑96.6% | 64↑107.8% | 31↓2.2% | 31 | |
| General & Administrative Expenses | 31↑62.5% | 19↑102.4% | 9↑46.2% | 6 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 31↑62.5% | 19↑102.4% | 9↑46.2% | 6 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 156↑88.9% | 82↑106.5% | 40↑5.9% | 38 | |
| Total Costs & Expenses | 156↑88.9% | 82↑106.5% | 40↑5.9% | 38 | |
| Operating Results | |||||
| Operating Income | -156↓88.9% | -82↓106.5% | -40↓5.9% | -38 | |
| Depreciation & Amortization | 0.11↑87.5% | 0.06↑194.7% | 0.02↑90.0% | 0.01 | |
| EBITDA | -156↓89.0% | -82↓106.5% | -40↓5.7% | -38 | |
| EBIT | -156↓88.9% | -82↓106.5% | -40↓5.7% | -38 | |
| Interest & Other Income | |||||
| Net Interest Income | 18↑22.6% | 15↑1009.7% | 1↑1316.7% | -0.11 | |
| Interest Income | 18↑22.6% | 15↑1009.7% | 1↑32750.0% | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.11 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00↓100.0% | 0.08 | |
| Other Income / Expenses | 18↑22.6% | 15↑220.6% | -12↓6331.4% | -0.19 | |
| Income Before Tax | -138↓103.1% | -68↓30.5% | -52↓37.4% | -38 | |
| Income Tax Expense | 0.22↑16.0% | 0.19↑3640.0% | 0.01↑400.0% | 0.00 | |
| Net Income & EPS | |||||
| Net Income from Continuing Operations | -138↓102.9% | -68↓30.8% | -52↓37.4% | -38 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -138↓102.9% | -68↓30.8% | -52↓37.4% | -38 | |
| Bottom-Line Net Income | -138↓102.9% | -68↓30.8% | -52↓37.4% | -38 | |
| EPS (Basic) | -2.52↓101.6% | -1.25↓25.0% | -1.00↓37.0% | -0.73 | |
| EPS (Diluted) | -2.52↓101.6% | -1.25↓25.0% | -1.00↓37.0% | -0.73 | |
| Weighted Average Shares | 55↑0.5% | 54↑5.1% | 52↑0.0% | 52 | |
| Weighted Average Diluted Shares | 55↑0.5% | 54↑5.1% | 52↑0.0% | 52 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.